miR‑101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3‑dependent apoptosis

Yin,Jiqing; Wang,Mingguo; Jin,Cuixiang; Qi,Qingguo

doi:10.3892/ol.2013.1725

miR‑101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3‑dependent apoptosis

Authors:
- Jiqing Yin
- Mingguo Wang
- Cuixiang Jin
- Qingguo Qi
View Affiliations

Affiliations: Department of General Practice, Shandong University Hospital, Jinan, Shandong 250061, P.R. China, Department of Stomatology, Subsidiary Central Hospital, Shandong University, Jinan, Shandong 250061, P.R. China, Department of Stomatology, Stomatology Hospital of Shandong University, Jinan, Shandong 250061, P.R. China
Published online on: December 3, 2013 https://doi.org/10.3892/ol.2013.1725
Pages: 461-465

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑101 (miR‑101) is evidently downregulated in several types of cancer, including non‑small cell lung cancer (NSCLC), and is crucial in sensitizing cells to chemotherapy drugs. The aim of the present study was to investigate the correlation between miR‑101 and chemosensitivity in the A549 NSCLC cell line. Here, we used the human A549 cell line for transfection with an miR-101 overexpressing vector and detected the cytotoxic acticity, proliferation and apoptosis of cis‑diaminedichloroplatinum (CDDP) in A549-miR-101 and A549-mock cells. We demonstrated that overexpression of miR‑101 sensitized A549 cells to CDDP, one of the most frequently used agents in curing or controlling NSCLC and enhanced CDDP‑induced cell death and caspase 3‑dependent apoptosis. In addition, miR‑101 facilitated the inhibitory role of CDDP in A549 cell colony formation. Overall, the results of the present study demonstrated that miR‑101 sensitizes the A549 NSCLC cell line to CDDP via the activation of caspase 3‑dependent apoptosis.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
4	Lee MW, Kim DS, Min NY and Kim HT: Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer. 122:2380–2384. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
7	Xu P, Guo M and Hay BA: MicroRNAs and the regulation of cell death. Trends Genet. 20:617–624. 2004. View Article : Google Scholar
8	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
9	Doench JG and Sharp PA: Specificity of microRNA target selection in translational repression. Genes Dev. 18:504–511. 2004. View Article : Google Scholar : PubMed/NCBI
10	Bentwich I, Avniel A, Karov Y, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
11	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
12	O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:2012010. View Article : Google Scholar
13	Smits M, Nilsson J, Mir SE, et al: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 1:710–720. 2010.PubMed/NCBI
14	Semaan A, Qazi AM, Seward S, et al: MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharm Res. 28:3079–3090. 2011. View Article : Google Scholar : PubMed/NCBI
15	Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
16	Pang Y, Young CY and Yuan H: MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 42:363–369. 2010. View Article : Google Scholar : PubMed/NCBI
17	Su H, Yang JR, Xu T, et al: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 81:1524–1529. 2011. View Article : Google Scholar : PubMed/NCBI
20	Batchu RB, Gruzdyn O, Qazi AM, Bouwman D, Gruber SA and Weaver DW: MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling via PRAS40. J Surg Res. 172:2332012. View Article : Google Scholar
21	Xu Y, An Y, Wang Y, et al: miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 29:2019–2024. 2013.PubMed/NCBI
22	Sachdeva M, Wu H, Ru P, Hwang L, Trieu V and Mo YY: MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene. 30:822–831. 2011. View Article : Google Scholar : PubMed/NCBI
23	Gui T and Shen K: miRNA-101: a potential target for tumor therapy. Cancer Epidemiol. 36:537–540. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chiang CW, Huang Y, Leong KW, et al: PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci. 17:352010. View Article : Google Scholar : PubMed/NCBI
25	Buechner J, Tomte E, Haug BH, et al: Tumor-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 105:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
26	Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008. View Article : Google Scholar : PubMed/NCBI